Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response

Journal of Proteome Research

Volumn 11, Issue 9, 2012, Pages 4630-4642

  Cunningham, Katharine ^a   Claus, Sandrine P ^b   Lindon, John C ^a   Holmes, Elaine ^a   Everett, Jeremy R ^c   Nicholson, Jeremy K ^a   Coen, Muireann ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

inter individual variability; isoniazid; NMR spectroscopy; pharmacometabonomics

Indexed keywords

ACETYLISONIAZID; BETA GLUCOSYLISONICOTINYLHYDRAZIDE; GLUCOSE; ISONIAZID; ISONIAZID DERIVATIVE; PYRUVATE ISONICOTINYLHYDRAZONE; PYRUVIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACETYLATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; HISTOPATHOLOGY; MALE; METABOLOMICS; NEUROTOXICITY; NONHUMAN; PHARMACOMETABONOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; URINE LEVEL;

ANIMALS; ISONIAZID; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; URINE;

ANIMALIA; RATTUS;

EID: 84866087835     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300430u     Document Type: Article

References (64)

1. Timbrell, J. A.; Mitchell, J. R.; Snodgrass, W. R.; Nelson, S. D. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo J. Pharmacol. Exp. Ther. 1980, 213 (2) 364-9 (Pubitemid 10109641)
2. Preziosi, P. Isoniazid: metabolic aspects and toxicological correlates Curr. Drug Metab. 2007, 8 (8) 839-51 (Pubitemid 350238914)
3. Nelson, S. D.; Mitchell, J. R.; Timbrell, J. A.; Snodgrass, W. R.; Corcoran, G. B., 3rd Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat Science 1976, 193 (4256) 901-3
4. Timbrell, J. A. The role of metabolism in the hepatotoxicity of isoniazid and iproniazid Drug Metab. Rev. 1979, 10 (1) 125-47 (Pubitemid 10185380)
5. Mitchell, J. R.; Zimmerman, H. J.; Ishak, K. G.; Thorgeirsson, U. P.; Timbrell, J. A.; Snodgrass, W. R.; Nelson, S. D. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis Ann. Intern. Med. 1976, 84 (2) 181-92
6. Ellard, G. A.; Gammon, P. T. Pharmacokinetics of isoniazid metabolism in man J. Pharmacokinet. Biopharm. 1976, 4 (2) 83-113 (Pubitemid 8133355)
7. Zamboni, V.; Defranceschi, A. Identification of isonicotinoylhydrazones of pyruvic and alpha-ketoglutaric acid in rat urine after treatment with isonicotinic acid hydrazide (isoniazid) Biochim. Biophys. Acta 1954, 14 (3) 430-2
8. Colvin, L. B. Metabolic fate of hydrazines and hydrazides J. Pharm. Sci. 1969, 58 (12) 1433-43
9. Peters, J. H.; Miller, K. S.; Brown, P. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man J. Pharmacol. Exp. Ther. 1965, 150 (2) 298-304
10. Wiegand, R. G. The formation of pyridoxal and pyridoxal 5-phosphate hydrazones1 J. Am. Chem. Soc. 1956, 78 (20) 5307-5309
11. Davison, A. N. Pyridoxal phosphate as coenzyme of diamine oxidase Biochem. J. 1956, 64 (3) 546-8
12. Peters, J. H.; Hayes, V. E. Comparative studies on the metabolism of isoniazid and isoniazid hydroazones in the dog Arch. Int. Pharmacodyn. Ther. 1966, 159 (2) 328-39
13. Devadatta, S.; Gangadharam, P. R.; Andrews, R. H.; Fox, W.; Ramakrishnan, C. V.; Selkon, J. B.; Velu, S. Peripheral neuritis due to isoniazid Bull. World Health Org. 1960, 23, 587-98
14. Shah, B. R.; Santucci, K.; Sinert, R.; Steiner, P. Acute isoniazid neurotoxicity in an urban hospital Pediatrics 1995, 95 (5) 700-4
15. Cash, J. M.; Zawada, E. T., Jr. Isoniazid overdose. Successful treatment with pyridoxine and hemodialysis West. J. Med. 1991, 155 (6) 644-6
16. Wood, J. D.; Peesker, S. J. The effect on GABA metabolism in brain of isonicotinic acid hydrazide and pyridoxine as a fuction of time after administration J. Neurochem. 1972, 19 (6) 1527-37
17. Snider, D. E., Jr. Pyridoxine supplementation during isoniazid therapy Tubercle 1980, 61 (4) 191-6
18. 6-deficient rats J. Biol. Chem. 1956, 221 (2) 781-9
19. Parkin, D. P.; Vandenplas, S.; Botha, F. J.; Vandenplas, M. L.; Seifart, H. I.; van Helden, P. D.; van der Walt, B. J.; Donald, P. R.; van Jaarsveld, P. P. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis Am. J. Respir. Crit. Care Med. 1997, 155 (5) 1717-22 (Pubitemid 27216683)
20. Sunahara, S.; Uranom; Ogawam Genetical and geographic studies on isoniazid inactivation Science 1961, 134 (3489) 1530-1
21. Cascorbi, I.; Drakoulis, N.; Brockmoller, J.; Maurer, A.; Sperling, K.; Roots, I. Arylamine N -acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity Am. J. Hum. Genet. 1995, 57 (3) 581-92
22. Hiratsuka, M.; Kishikawa, Y.; Takekuma, Y.; Matsuura, M.; Narahara, K.; Inoue, T.; Hamdy, S. I.; Endo, N.; Goto, J.; Mizugaki, M. Genotyping of the N -acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients Drug Metab. Pharmacokinet. 2002, 17 (4) 357-62
23. Yard, A. S.; McKennis, H., Jr. Aspects of the metabolism of isoniazid and acetylisoniazid in the human and the dog J. Med. Pharm. Chem. 1962, 52, 196-203
24. Nicholson, J. K.; Lindon, J. C.; Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data Xenobiotica 1999, 29 (11) 1181-9
25. Lindon, J. C.; Nicholson, J. K.; Holmes, E.; Everett, J. R. Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids Concepts Magn. Reson. 2000, 12 (5) 289-320
26. Gavaghan, C. L.; Holmes, E.; Lenz, E.; Wilson, I. D.; Nicholson, J. K. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk: ApfCD mouse FEBS Lett. 2000, 484 (3) 169-174
27. Nicholson, J. K.; Wilson, I. D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism Nat. Rev. Drug Discovery 2003, 2 (8) 668-76 (Pubitemid 37361770)
28. Lindon, J. C.; Holmes, E.; Nicholson, J. K. Toxicological applications of magnetic resonance Prog. Nucl. Magn. Reson. Spectrosc. 2004, 45 (1-2) 109-143
29. Coen, M.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology Chem. Res. Toxicol. 2008, 21 (1) 9-27 (Pubitemid 351219705)
30. Mortishire-Smith, R. J.; Skiles, G. L.; Lawrence, J. W.; Spence, S.; Nicholls, A. W.; Johnson, B. A.; Nicholson, J. K. Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity Chem. Res. Toxicol. 2004, 17 (2) 165-73 (Pubitemid 38252496)
31. 1H-NMR spectral patterns Biomarkers 2004, 9 (4-5) 364-85 (Pubitemid 40100627)
32. Coen, M.; Hong, Y. S.; Clayton, T. A.; Rohde, C. M.; Pearce, J. T.; Reily, M. D.; Robertson, D. G.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. The mechanism of galactosamine toxicity revisited; a metabonomic study J. Proteome Res. 2007, 6 (7) 2711-9 (Pubitemid 47122366)
33. Shipkova, P.; Vassallo, J. D.; Aranibar, N.; Hnatyshyn, S.; Zhang, H.; Clayton, T. A.; Cantor, G. H.; Sanders, M.; Coen, M.; Lindon, J. C.; Holmes, E.; Nicholson, J. K.; Lehman-McKeeman, L. Urinary metabolites of 2-bromoethanamine identified by stable isotope labelling: evidence for carbamoylation and glutathione conjugation Xenobiotica 2010, 41 (2) 144-54
34. Coen, M.; Want, E. J.; Clayton, T. A.; Rhode, C. M.; Hong, Y. S.; Keun, H. C.; Cantor, G. H.; Metz, A. L.; Robertson, D. G.; Reily, M. D.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Mechanistic aspects and novel biomarkers of responder and non-responder phenotypes in galactosamine-induced hepatitis J. Proteome Re.s 2009, 8 (11) 5175-87
35. Holmes, E.; Bonner, F. W.; Sweatman, B. C.; Lindon, J. C.; Beddell, C. R.; Rahr, E.; Nicholson, J. K. Nuclear-magnetic-resonance spectroscopy and pattern-recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine Mol. Pharmacol. 1992, 42 (5) 922-930 (Pubitemid 23021498)
36. Yap, I. K.; Clayton, T. A.; Tang, H.; Everett, J. R.; Hanton, G.; Provost, J. P.; Le Net, J. L.; Charuel, C.; Lindon, J. C.; Nicholson, J. K. An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate J. Proteome Res. 2006, 5 (10) 2675-84 (Pubitemid 44595169)
37. Bohus, E.; Coen, M.; Keun, H. C.; Ebbels, T. M.; Beckonert, O.; Lindon, J. C.; Holmes, E.; Noszal, B.; Nicholson, J. K. Temporal metabonomic modeling of L-arginine-induced exocrine pancreatitis J. Proteome Res. 2008, 7 (10) 4435-45
38. Nicholson, J. K. Global systems biology, personalized medicine and molecular epidemiology Mol. Syst. Biol. 2006, 2, 52
39. Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (34) 14187-8
40. Clayton, T. A.; Lindon, J. C.; Cloarec, O.; Antti, H.; Charuel, C.; Hanton, G.; Provost, J. P.; Le Net, J. L.; Baker, D.; Walley, R. J.; Everett, J. R.; Nicholson, J. K. Pharmaco-metabonomic phenotyping and personalized drug treatment Nature 2006, 440 (7087) 1073-7
41. Clayton, T. A.; Baker, D.; Lindon, J. C.; Everett, J. R.; Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (34) 14728-33
42. Winnike, J. H.; Li, Z.; Wright, F. A.; Macdonald, J. M.; O'Connell, T. M.; Watkins, P. B. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans Clin. Pharmacol. Ther. 2010, 88 (1) 45-51
43. Backshall, A.; Sharma, R.; Clarke, S. J.; Keun, H. C. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine Clin. Cancer Res. 2011, 17 (9) 3019-28
44. Stebbing, J.; Sharma, A.; North, B.; Athersuch, T. J.; Zebrowski, A.; Pchejetski, D.; Coombes, R. C.; Nicholson, J. K.; Keun, H. C. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy Ann. Oncol. 2012, 23, 860-6
45. Beckonert, O.; Keun, H. C.; Ebbels, T. M.; Bundy, J.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts Nat. Protoc. 2007, 2 (11) 2692-703
46. Aue, W. P.; Bartholdi, E.; Ernst, R. R. Two-dimensional spectroscopy. Application to nuclear magnetic resonance J. Chem. Phys. 1976, 64 (5) 2229-46
47. Braunschweiler, L.; Ernst, R. R. Coherence transfer by isotropic mixing-application to proton correlation spectroscopy J. Magn. Reson. 1983, 53 (3) 521-528
48. Aue, W. P.; Karhan, J.; Ernst, R. R. Homonuclear broad-band decoupling and 2-dimensional J-resolved NMR-spectroscopy J. Chem. Phys. 1976, 64 (10) 4226-4227
49. Bodenhausen, G.; Ruben, D. J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy Chem. Phys. Lett. 1980, 69, 185
50. Bax, A.; Summers, M. F. Proton and carbon-13 assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR J. Am. Chem. Soc. 1986, 108, 2093-2094
51. 1h NMR spectra for improved metabolic biomarker recovery Anal. Chem. 2009, 81 (1) 56-66
52. 1H NMR metabonomics Anal. Chem. 2006, 78 (13) 4281-90
53. Trygg, J.; Holmes, E.; Lundstedt, T. Chemometrics in metabonomics J. Proteome Res. 2007, 6 (2) 469-79 (Pubitemid 46340151)
54. Trygg, J.; Wold, S. O2-PLS, a two-block (X-Y) latent variable regression (LVR) method with an integral OSC filter J. Chemom. 2003, 17 (1) 53-64
55. 1H NMR spectroscopic metabonomic studies Anal. Chem. 2005, 77 (2) 517-26 (Pubitemid 40116831)
56. Fox, H. H. Synthetic tuberculostats. VI. Some sugar derivatives of isonicotinylhydrazine J. Org. Chem. 1953, 18 (8) 990-993
57. Sumner, S. J.; Burgess, J. P.; Snyder, R. W.; Popp, J. A.; Fennell, T. R. Metabolomics of urine for the assessment of microvesicular lipid accumulation in the liver following isoniazid exposure Metabolomics 2010, 6 (2) 238-249
58. O'Brien, P. J.; Slaughter, M. R.; Polley, S. R.; Kramer, K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats Lab. Anim. 2002, 36 (3) 313-21 (Pubitemid 34785766)
59. 6 in the toxicity of hydrazines Ann. N.Y. Acad. Sci. 1969, 166 (1) 136-45
60. Lightcap, E. S.; Silverman, R. B. Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues J. Med. Chem. 1996, 39 (3) 686-94 (Pubitemid 26065822)
61. Timbrell, J. A.; Wright, J. M. Studies on the effects of isoniazid on acetylhydrazine metabolism in vivo and in vitro Drug Metab. Dispos. 1979, 7 (4) 237-40 (Pubitemid 10225172)
62. Okutur, S. K. Acute isoniazid intoxication: Convulsion, rhabdomyolysis and metabolic acidosis Turk. J. Med. Sci. 2006, 36 (6) 397
63. Alvarez, F. G.; Guntupalli, K. K. Isoniazid overdose: four case reports and review of the literature Intensive Care Med. 1995, 21 (8) 641-4
64. Chin, L.; Sievers, M. L.; Herrier, R. N.; Picchioni, A. L. Convulsions as the etiology of lactic acidosis in acute isoniazid toxicity in dogs Toxicol. Appl. Pharmacol. 1979, 49 (2) 377-84 (Pubitemid 9191866)